1. Identification of coronary heart disease biomarkers with different severities of coronary stenosis in human urine using non-targeted metabolomics based on UPLC-Q-TOF/MS
- Author
-
Chunquan Yu, Mengnan Huang, Zhu Li, Yubo Li, Huan Zhao, Xuemeng Cai, Shan Gao, Yuechen Liu, Lin Li, Yijia Liu, and Tianpu Zhang
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,Clinical Biochemistry ,Coronary Disease ,Coronary stenosis ,Urine ,Biochemistry ,Severity of Illness Index ,Mass Spectrometry ,Pathogenesis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Metabolomics ,Internal medicine ,medicine ,Humans ,Chromatography, High Pressure Liquid ,Cause of death ,Aged ,Aged, 80 and over ,Fatty acid metabolism ,business.industry ,Biochemistry (medical) ,Coronary Stenosis ,General Medicine ,Middle Aged ,medicine.disease ,Coronary heart disease ,Stenosis ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cardiology ,Female ,business ,Biomarkers - Abstract
Background Coronary heart disease (CHD) is the leading cause of death worldwide, and its pathogenesis has attracted much attention. Metabolomics serves as an important tool for diagnosing diseases and exploring their pathogenesis in recent years. In this study, CHD patients were studied by comparing them with normal subjects to elucidate biomarkers that are linearly correlated with the severity of coronary stenosis. Methods An ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) was used to analyze the urine metabolites of CHD patients and normal subjects. A total of 131 subjects included 27 patients who presented with 50–69% coronary stenosis, 22 with 70–89% stenosis, 29 with 90–99% stenosis, 24 with 100% stenosis, and 29 normal subjects. Results A total of 14 potential biomarkers associated with CHD were identified, and among them 4 biomarkers were linearly correlated with the severity of coronary stenosis in CHD patients. The metabolic pathways involved were amino acid metabolism, fatty acid metabolism, energy metabolism, and other pathways. Conclusion This study identified the biomarkers and metabolic pathways that may be involved in the occurrence and development of CHD, laying a theoretical foundation for better diagnosis and treatment of CHD in the future.
- Published
- 2019